Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.15.6397

Loss of Expression and Aberrant Methylation of the CDH1 (E-cadherin) Gene in Breast Cancer Patients from Kashmir  

Asiaf, Asia (Department of Biochemistry, Faculty of Biological Science, University of Kashmir)
Ahmad, Shiekh Tanveer (Clarke H. Smith Brain Tumour Centre, University of Calgary)
Aziz, Sheikh Aejaz (Department of Medical Oncology, Sher-I-Kashmir Institute of Medical Sciences)
Malik, Ajaz Ahmad (Department Of General Surgery, Sher-I-Kashmir Institute of Medical Sciences)
Rasool, Zubaida (Department Of Pathology, Sher-I-Kashmir Institute of Medical Sciences)
Masood, Akbar (Department of Biochemistry, Faculty of Biological Science, University of Kashmir)
Zargar, Mohammad Afzal (Department of Biochemistry, Faculty of Biological Science, University of Kashmir)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.15, 2014 , pp. 6397-6403 More about this Journal
Abstract
Background: Aberrant promoter hypermethylation has been recognized in human breast carcinogenesis as a frequent molecular alteration associated with the loss of expression of a number of key regulatory genes and may serve as a biomarker. The E-cadherin gene (CDH1), mapping at chromosome 16q22, is an intercellular adhesion molecule in epithelial cells, which plays an important role in establishing and maintaining intercellular connections. The aim of our study was to assess the methylation pattern of CDH1 and to correlate it with the expression of E-cadherin, clinicopathological parameters and hormone receptor status in breast cancer patients of Kashmir. Materials and Methods: Methylation specific PCR (MSP) was used to determine the methylation status of CDH1 in 128 invasive ductal carcinomas (IDCs) paired with the corresponding normal tissue samples. Immunohistochemistry was used to study the expression of E-cadherin, ER and PR. Results: CDH1 hypermethylation was detected in 57.8% of cases and 14.8% of normal adjacent controls. Reduced levels of E-cadherin protein were observed in 71.9% of our samples. Loss of E-cadherin expression was significantly associated with the CDH1 promoter region methylation (p<0.05, OR=3.48, CI: 1.55-7.79). Hypermethylation of CDH1 was significantly associated with age at diagnosis (p=0.030), tumor size (p=0.008), tumor grade (p=0.024) and rate of node positivity or metastasis (p=0.043). Conclusions: Our preliminary findings suggest that abnormal CDH1 methylation occurs in high frequencies in infiltrating breast cancers associated with a decrease in E-cadherin expression. We found significant differences in tumor-related CDH1 gene methylation patterns relevant to tumor grade, tumor size, nodal involvement and age at diagnosis of breast tumors, which could be extended in future to provide diagnostic and prognostic information.
Keywords
E-cadherin; ER; invasive ductal carcinoma; kashmir; promoter methylation;
Citations & Related Records
Times Cited By KSCI : 5  (Citation Analysis)
연도 인용수 순위
1 Acs G, Lawton TJ, Rebbeck TR, et al (2001). Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Path, 115, 85-98.   DOI   ScienceOn
2 Andrews JL, Kim AC, Hens JR (2012). The role and function of cadherins in the mammary gland. Breast Cancer Res, 14, 203-13.
3 Baylin SB, Herman JG (2000). DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet, 16, 168-74.   DOI   ScienceOn
4 Berx G, Cleton-Jansen AM, Nollet F, et al (1995). E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J, 14, 6107.
5 Brock MV, Gou M, Akiyama Y, et al (2003). Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin cancer res, 9, 2912-9.
6 Caldeira JRF, Prando EC, Quevedo FC, et al (2006). CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC cancer, 6, 48.   DOI
7 Cavallaro U, Christofori G (2004). Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer, 4, 118-32.   DOI   ScienceOn
8 Debies MT, Welch DR (2001). Genetic basis of human breast cancer metastasis. J Mammary Gland Biol Neoplasia, 6, 441-51.   DOI
9 Elledge RM, Green S, Pugh R, et al (2000). Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study. Int J Cancer, 89, 111-7.   DOI
10 Fisher B, Redmond C, Brown A, et al (1983). Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol, 1, 227-41.
11 Graff JR, Gabrielson E, Fujii H, et al (2000). Methylation patterns of the E-cadherin 5'- CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem, 275, 2727-32.   DOI   ScienceOn
12 Graff JR, Herman JG, Lapidus RG, et al (1995). E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res, 55, 5195-9.
13 Hirohashi S (1998). Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Path, 153, 333-9.   DOI   ScienceOn
14 Hajra KM, Ji X, Fearon ER (1999). Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene, 18.
15 Harvey JM, Clark GM, Osborne CK, et al (1999). Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol, 17, 1474-.
16 Hennig G, Lowrick O, Birchmeier W, et al (1996). Mechanisms identified in the transcriptional control of epithelial gene expression. J Biol Chem, 271, 595-602.   DOI
17 Hu X-C, Loo WTY, Chow LWC (2002). E-cadherin promoter methylation can regulate its expression in invasive ductal breast cancer tissue in Chinese woman. Life sci, 71, 1397-404.   DOI   ScienceOn
18 Issa JP, Ahuja N (2000). Aging, methylation and cancer. Histol Histopathol, 15, 835-42.
19 Kanai Y, Oda T, Tsuda H, et al (1994). Point mutation of the ecadherin gene in invasive lobular carcinoma of the breast. Cancer Sci, 85, 1035-9.   DOI
20 Kowalski PJ, Rubin MA, Kleer CG (2003). E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res, 5, 217-22.   DOI
21 Li S, Rong M, Iacopetta B (2006). DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett, 237, 272-80.   DOI   ScienceOn
22 Lo P-K, Sukumar S (2008). Epigenomics and breast cancer. Pharmacogenomics.
23 Overduin M, Harvey TS, Bagby S, et al (1995). Solution structure of the epithelial cadherin domain responsible for selective cell adhesion. Science, 267, 386-9.   DOI
24 Lombaerts M, Middeldorp JW, van der Weide E, et al (2004). Infiltrating leukocytes confound the detection of E-cadherin promoter methylation in tumors. Biochem Bioph Res Co, 319, 697-704.   DOI
25 Nass SJ, Herman JG, Gabrielson E, et al (2000). Aberrant methylation of the estrogen receptor and E-cadherin 5 CpG islands increases with malignant progression in human breast cancer. Cancer Res, 60, 4346-8.
26 Oka H, Shiozaki H, Kobayashi K, et al (1992). Correlation between E-cadherin expression and metastasis in human breast cancer: preliminary report. Nihon Geka Gakkai zasshi, 93, 105.
27 Peinado H, Ballestar E, Esteller M, et al (2004). Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol, 24, 306-19.   DOI   ScienceOn
28 Prasad CP, Mirza S, Sharma G, et al (2008). Epigenetic alterations of CDH1 and APC genes: Relationship with activation of Wnt/beta- catenin pathway in invasive ductal carcinoma of breast. Life Sci, 83, 318-25.   DOI
29 Raish M, Dhillon VS, Ahmad A, et al (2009). Promoter hypermethylation in tumor suppressing genes p16 and FHIT and their relationship with estrogen receptor and progesterone receptor status in breast cancer patients from Northern India. Transl Oncol, 2, 264.   DOI
30 Ronneberg JA, Fleischer T, Solvang HK, et al Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol, 5, 61-76.
31 Sebova K, Zmetakova I, Bella V, et al (2011). RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer. Cancer Epidemiol Biomarkers Prev, 10, 13-26.
32 Rose C, Andersen K, Mouridsen H, et al (1985). Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. The Lancet, 325, 16-9.   DOI
33 Sadot E, Simcha I, Shtutman M, et al (1998). Inhibition of $\beta$-catenin-mediated transactivation by cadherin derivatives. Proc Natl Acad Sci USA, 95, 15339-44.   DOI
34 Sarrio D, Perez-Mies B, Hardisson D, et al (2004). Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene, 23, 3272-83.   DOI   ScienceOn
35 Shargh SA, Sakizli M, Farajnia S, et al (2011). Evaluation of methylation pattern in promoter region of E-cadherin gene and its relation to tumor grade and stage in breast cancer. Afr J Biotechnol, 10, 1745-51.
36 Shinozaki M, Hoon DSB, Giuliano AE, et al (2005). Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res, 11, 2156-62.   DOI   ScienceOn
37 Syeed N, Husain SA, Abdullah S, et al (2010). Caveolin-1 promotes mammary tumorigenesis: mutational profile of the Kashmiri population. Asian Pac J Cancer Prev, 11, 689-96.
38 Szyf M, Pakneshan P, Rabbani SA (2004). DNA methylation and breast cancer. Bioche Pharmacol, 68, 1187-97.   DOI   ScienceOn
39 Tamura G, Yin J, Wang S, et al (2000). E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst, 92, 569-73.   DOI   ScienceOn
40 Tao MH, Shields PG, Nie J, et al (2009). DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Tr, 114, 559-68.   DOI
41 Valavaara R, Tuominen J, Johansson R (1990). Predictive value of tumor estrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene. Cancer, 66, 2264-9.   DOI
42 Vos CB, Cleton-Jansen AM, Berx G, et al (1997). E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer, 76, 1131.   DOI   ScienceOn
43 Wani SQ, Khan T, Wani SY, et al (2012). Clinicoepidemiological analysis of female breast cancer patients in Kashmir. J Can Res Ther, 8, 389.   DOI
44 Xiong H-L, Liu X-Q, Sun A-H, et al (2013). Aberrant DNA methylation of P16, MGMT, hMLH1 and hMSH2 genes in combination with the MTHFR C677T genetic polymorphism in gastric cancer. Asian Pac J Cancer Prev, 14, 3139-42.   과학기술학회마을   DOI
45 Yang X, Yan L, Davidson NE (2001). DNA methylation in breast cancer. Endocr-Relat Cancer, 8, 115-27.   DOI   ScienceOn
46 Yoder BJ, Wilkinson EJ, Massoll NA (2007). Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast. Breast J, 13, 172-9.   DOI   ScienceOn
47 Yoshida R, Kimura N, Harada Y, et al (2001). The loss of E-cadherin, $\alpha$ and $\beta$-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. Int J Oncol, 18, 513.
48 Yuan Y-L, Wang Y-M, Liu H, et al (2012). Aberrant expression of e-cadherin in lung tissues of patients with probable lung cancer. Asian Pac J Cancer Prev, 13, 5149-53.   과학기술학회마을   DOI
49 Zheng, Shi-Ying, Hou, et al (2012). Clinical outcomes of downregulation of E-cadherin gene expression in non-small cell lung cancer. Asian Pac J Cancer Prev, 13, 1557-61.   과학기술학회마을   DOI
50 Mir MR, Shabir N, Wani KA, et al (2012). Association between p16, hMLH1 and E-cadherin promoter hypermethylation and intake of local hot salted tea and sun-dried foods in Kashmiris with gastric tumors. Asian Pac J Cancer Prev, 13, 181-6.   과학기술학회마을   DOI   ScienceOn
51 Sofi GN, Sofi JN, Nadeem R, et al (2012). Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement. Asian Pac J Cancer Prev, 13, 5047-52.   과학기술학회마을   DOI   ScienceOn